In agreement, only WT-FF mice developed increased IR and impaired GT at 12 and 24 weeks (Figs 7 and 8 and S-Fig. 3), supporting the notion that the absence or blocking of CYP2E1 may be beneficiary for not only preventing increased IR and impaired GT but also preventing advanced liver disease such as NASH and fibrosis. The gene discussed is CYP2E1; the disease is metabolic dysfunction-associated steatohepatitis.